Assessing changes in relapse rates in multiple sclerosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Multiple Sclerosis

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458510379246PMID 20810517
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

  2010cited by this paper
• INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL

  2009cited by this paper
• Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

  2008cited by this paper
• Intravenous immunoglobulin in relapsing-remitting multiple sclerosis

  2008cited by this paper
• Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Clinical outcome measures in multiple sclerosis.

  2007cited by this paper
• A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis

  2007cited by this paper
• Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.

  2006cited by this paper
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• Oral fingolimod (FTY720) for relapsing multiple sclerosis.

  2006cited by this paper
• A randomized study of two interferon- beta treatments in relapsing–remitting multiple sclerosis

  2006cited by this paper
• Randomized study of once-weekly interferon β-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

  2005cited by this paper
• Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.

  2005cited by this paper
• A controlled trial of natalizumab for relapsing multiple sclerosis.

  2003cited by this paper
• A randomized, double-blind, placebo-controlled MRI study of anti–herpes virus therapy in MS

  2002cited by this paper
• No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment

  2002cited by this paper
• Problems in Clinical Trial Design in Multiple Sclerosis

  2002cited by this paper
• Interferon in relapsing-remitting multiple sclerosis.

  2001influential reference
• PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS

  2001cited by this paper
• Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

  2001cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• Ingested IFN-α

  2001cited by this paper
• Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

  1999cited by this paper
• TNF neutralization in MS

  1999cited by this paper
• Interferon-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis

  1999cited by this paper
• Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

  1999cited by this paper
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

  1998cited by this paper
• Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study

  1997cited by this paper
• Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.

  1997cited by this paper
• Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

  1997cited by this paper
• Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

  1996cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996influential reference
• Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

  1996cited by this paper
• Acyclovir treatment of relapsing-remitting multiple sclerosis

  1996cited by this paper
• Intravenous immunoglobulin treatment in multiple sclerosis.

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

  1995influential reference
• Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

  1995cited by this paper
• A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients

  1995cited by this paper
• A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

  1995cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• The efficacy of azathioprine in relapsing ‐ remitting multiple sclerosis

  1991cited by this paper
• Systemic alpha‐interferon therapy of multiple sclerosis

  1984cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983influential reference
• Intrathecal interferon reduces exacerbations of multiple sclerosis.

  1981cited by this paper

• Mathematical Modelling of Disability Progression in Patients with Multiple Sclerosis

  2025influential citation
• Placebo Responses in Trials for Multiple Sclerosis.

  2025cites this paper
• Managing reactivation of multiple sclerosis during treatment with natalizumab

  2025cites this paper
• Graph Domain Adaptation with Dual-branch Encoder and Two-level Alignment for Whole Slide Image-based Survival Prediction

  2024cites this paper
• Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study

  2024influential citation
• Sclerosi multipla: aspetti evolutivi e prognostici

  2024cites this paper
• Parenchymal Neuro-Behçet's disease or Comorbid Behçet's disease with multiple sclerosis: A discriminative analysis of a complex clinical entity.

  2024cites this paper
• Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review

  2024cites this paper
• Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data

  2024cites this paper
• Sclérose en plaques : aspects évolutifs et pronostiques

  2024cites this paper
• ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy

  2023cites this paper
• Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis

  2023cites this paper
• Multiple types of relapses in MOG antibody disease.

  2023cites this paper
• Impact of menopause on relapse rate and disability level in patients with multiple sclerosis (MS): a systematic review and meta-analysis

  2023cites this paper
• Estimating the disutility of relapse in relapsing–remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models

  2023cites this paper
• Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study

  2023influential citation
• “Can I exercise? Would it help? Would it not?”: exploring the experiences of people with relapsing remitting multiple sclerosis engaging with physical activity during a relapse: a qualitative study

  2022cites this paper
• Multiple sclerosis and related disorders: where do we stand in 2022?

  2022cites this paper
• Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease

  2021cites this paper
• Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review

  2021cites this paper
• The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis

  2021cites this paper
• Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.

  2020cites this paper
• Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: a systematic review and meta-analysis of 43 randomized placebo-controlled trials

  2020influential citation
• Patient‐ versus physician‐reported relapses in multiple sclerosis: insights from a large observational study

  2020cites this paper
• Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis

  2020cites this paper
• Relapses in multiple sclerosis reported by patients versus physicians - Insights from a large observational study.

  2020cites this paper
• Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review

  2020cites this paper
• Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes.

  2020cites this paper
• Exercise in the management of multiple sclerosis relapses: current evidence and future perspectives.

  2020cites this paper
• Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis

  2019cites this paper
• Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis.

  2019cites this paper
• Management of Multiple Sclerosis Relapses.

  2019cites this paper
• Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran

  2019cites this paper
• Factors Involved in Relapse of Multiple Sclerosis

  2019cites this paper
• Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

  2019cites this paper
• Multiple Sclerosis Performance Test: Technical Development and Usability

  2019cites this paper
• Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme

  2019cites this paper
• Immunoglobulin G index as a biomarker of relapse response to corticosteroids during early stages of multiple sclerosis.

  2019cites this paper
• Real-world studies provide reliable comparisons of disease modifying therapies in MS – Yes

  2019cites this paper
• Sample size calculation for the Andersen‐Gill model comparing rates of recurrent events

  2019influential citation
• HERNDON AWARD FOR OUTSTANDING IJMSC ARTICLE

  2018cites this paper
• UNIVERSITY OF GENOVA DEPARTMENT OF HEALTH SCIENCES ACADEMIC YEAR 2017/2018 Thesis for the Degree as Doctor of Philosophy in prevention of cancer and of chronic degenerative diseases and biostatistics

  2018cites this paper
• Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme

  2018cites this paper
• Cost - effectiveness and Cost - utility of CinnoVex versus ReciGen in Patients with Relapsing - Remitting Multiple Sclerosis in Iran

  2018cites this paper
• Factors Associated with Postrelapse Rehabilitation Use in Multiple Sclerosis: A Pilot Survey.

  2018cites this paper
• Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials

  2018cites this paper
• Trials of Novel Therapies Specifically for Progressive MS

  2018cites this paper
• Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS

  2017cites this paper
• Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia

  2017cites this paper
• Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

  2017cites this paper
• Impairment of decision-making in multiple sclerosis: A neuroeconomic approach

  2017cites this paper
• Relapses in Multiple Sclerosis: Definition, Pathophysiology, Features, Imitators, and Treatment

  2016cites this paper
• Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.

  2016cites this paper
• Assessing Functional Decline in Neurological Diseases Clinical Trials: Duration of Follow-Up - The Case of Multiple Sclerosis.

  2016cites this paper
• Biopsychosocial comparison of adherent versus nonadherent multiple sclerosis patients

  2016cites this paper
• Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.

  2016cites this paper
• Sample Size Estimation for Negative Binomial Regression Comparing Rates of Recurrent Events with Unequal Follow-Up Time

  2015cites this paper
• Natural history of multiple sclerosis from the Indian perspective: Experience from a tertiary care hospital.

  2015cites this paper
• Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

  2015cites this paper
• Relapse in multiple sclerosis

  2015cites this paper
• The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care

  2015cites this paper
• Nuovi schemi terapeutici nella sclerosi multipla

  2015cites this paper
• Evaluating response to disease-modifying therapy in relapsing multiple sclerosis

  2015cites this paper
• Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

  2015cites this paper
• Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review

  2015cites this paper
• Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?

  2015influential citation
• Functional clinical outcomes in multiple sclerosis: Current status and future prospects.

  2015cites this paper
• Can we measure long-term treatment effects in multiple sclerosis?

  2015cites this paper
• Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

  2015cites this paper
• Impact of multiple sclerosis relapse: The NARCOMS participant perspective.

  2015cites this paper
• EDSS progression in placebo cohorts in relapsing MS : A systematic review and meta-regression

  2015cites this paper
• Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator

  2015cites this paper
• Risk stratification and mitigation multiple sclerosis.

  2014cites this paper
• Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study

  2014cites this paper
• Web scraping technologies in an API world

  2014cites this paper
• Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

  2014cites this paper
• Implications for multiple sclerosis in the era of the Affordable Care Act: an evolving treatment paradigm.

  2014cites this paper
• Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

  2014cites this paper
• Rehabilitation interventions for the management of multiple sclerosis relapse: a short scoping review.

  2014cites this paper
• Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis

  2014cites this paper
• Verblindete Fallzahlanpassung in klinischen Studien mit Ereigniszähldaten

  2014cites this paper
• Time to first relapse as an endpoint in multiple sclerosis clinical trials

  2013cites this paper
• Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression

  2013influential citation
• Comparison of disability and relapse outcomes in randomised, placebo controlled trials in relapsing multiple sclerosis: A systematic review and meta-regression

  2013influential citation
• Defining and scoring response to IFN-β in multiple sclerosis

  2013cites this paper
• Personalized Management of Multiple Sclerosis

  2013cites this paper
• MRI as a surrogate marker for clinical outcomes in multiple sclerosis

  2013cites this paper
• Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

  2013cites this paper
• Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

  2013cites this paper
• Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

  2013cites this paper
• Prognostic Risk Estimates of Patients with Multiple Sclerosis and Their Physicians: Comparison to an Online Analytical Risk Counseling Tool

  2013cites this paper
• Randomized study combining interferon and glatiramer acetate in multiple sclerosis

  2013cites this paper
• Evidence for Long-Term Use of Intramuscular Interferon Beta-1a: An Overview of Relapse, Disability, and MRI Data from Selected Clinical Trials

  2013cites this paper
• A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design

  2012cites this paper
• Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data

  2012cites this paper
• Statistical cures and other fallacies

  2012cites this paper
• Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis

  2012cites this paper
• Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod

  2012cites this paper
• multiple sclerosis : A systematic review and meta-analysis Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing

  2012cites this paper
• Disease activity free status in MS.

  2012cites this paper